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Summary
Stiff-Man syndrome (SMS) is a rare disease of the central nervous system (CNS) characterized
by progressive rigidity ofthe body musculature with superimposed painful spasms. An autoimmune
origin of the disease has been proposed . In a caseload of more than 100 SMS patients, 60%
were found positive for autoantibodies directed against the GABA-synthesizing enzyme glutamic
acid decarboxylase (GAD). Few patients, all women affected by breast cancer, were negative for
GAD autoantibodies but positive for autoantibodies directed against a 128-kD synaptic protein .
We report here that this antigen is amphiphysin . GAD and amphiphysin are nonintrinsic membrane
proteins that are concentrated in nerve terminals, where a pool of both proteins is associated
with the cytoplasmic surface of synaptic vesicles. GAD and amphiphysin are the only two known
targets of CNS autoimmunity with this distribution. This finding suggests a possible link between
autoimmunity directed against rytoplasmic proteins associated with synaptic vesicles and SMS.
Stiff-Man syndrome (SMS) is a rare human central nervoussystem (CNS) disease, characterized by chronic rigidity
of the body musculature with superimposed painful spasms
(1) . It is thought to result from an impairment of inhibitory
pathways that control motor neuron activity (2-4) . It was
previously suggested that SMS may have an autoimmune
pathogenesis . 60% of the patients affected by this condition
are positive in their serum and cerebrospinal fluid (CSF) for
autoantibodies directed against the GABA-synthesizing en-
zyme glutamic acid decarboxylase (GAD) (5-8) . In our cur-
rent caseload of 119 patients referred to us with a clinical
diagnosis ofSMS, 72 were found positive for these autoanti-
bodies (Guarnaccia, J., M. Solimena, K. Marek, and P. De
Camilli, unpublished observations) . In the SMS patient sub-
population positive for GAD autoantibodies, a frequent oc-
currence ofinsulin-dependent diabetes mellitus and of other
organ-specific autoimmune diseases is observed (6, 7) .
We have recently described three female patients with SMS
and breast cancer and no signs of organ-specific autoimmune
diseases . These three patients (referred to henceforth as pa-
tients BC-SMS 1, 2, and 3, respectively) were negative for
GAD autoantibodies but were positive for autoantibodies
directed against a 128-kD neuronal antigen concentrated at
synapses (9) . We have now identified a fourth patient with
both breast cancer and SMS syndrome. This patient (BC-SMS
4), as well, was positive for autoantibodies to the 128-kD
protein (this study) . The characterization of this autoantigen
is crucial to the elucidation of pathogenetic mechanisms in
SMS with breast cancer.
Recently, a novel synaptic vesicle-associated protein, am-
phiphysin, was described (10) . This protein was identified
by screening a chicken brain Xgt11 library with antibodies
raised against chicken brain synaptic proteins . Amphiphysin,
an acidic protein present in chicken as well as in mammalian
nervous tissue, was shown by immunocytochemistry to be
concentrated in nerve terminals. A large fraction of am-
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phiphysin is present in cytosolic fractions ofbrain homogenates
but a pool ofthe protein is recovered in a tightly boundform
in highly purified synaptic vesicles, although the protein is
not enriched on these organelles (10) . Some of the properties
ofamphiphysin were reminiscent of the properties of the 128-
kD antigen (10) . Therefore, a detailed comparison of the char-
acteristics ofthe two proteins was performed. We report here
that the 128-kD antigen is amphiphysin.
Materials and Methods
Materials.
	
Three sera of SMS patients affected by breast cancer
were previously described (9) . These sera, defined BC-SMS 1, 2,
and 3, correspond to sera of patients 1, 2, and 3, respectively, of
reference 9 . Serum BC-SMS 4 is from a new patient with both
conditions. A GAD autoantibody-positive human serum is from
ourcaseload of SMS sera (6, 8) . Rabbit polyclonal antibodies directed
against a,d-galactosidase chicken amphiphysin fusion protein were
previously described (10) . These antibodies were shown to recog-
nize rat amphiphysin (10). Rabbit sera directed against synaptophysin
(11) and GAD (serum no . 6799 (12)) were the kind gift of Dr. R.
Jahn (Yale University, NewHaven, CT), and Drs. Z. Katarova and
G. Szabo (Hungarian Academy of Sciences, Szeged, Hungary),
respectively. Small-scale lysates of bacteria expressing (3-galactosidase
fusion proteins were prepared according to reference 13 . J3rC3 and
ciTC9 cell lines were the kind gift of Drs. D. Hanahan (University
of California, San Francisco, CA), S. Efrat (Albert Einstein Col-
lege of Medicine, New York, NewYork), and E. Leiter (Jackson
Laboratories, Bar Harbor, ME), and PC12 cells were the gift of
Dr. L. Greene (Columbia University, New York).
Western Blotting ofOne-and Two-dimensional Gels. Total rat brain
homogenate was prepared as described (6, 14) . Postnuclear super-
natants ofrat tissues and of cell lines were prepared by homogeni-
zation in 10 vol of ice-cold 10 mM Hepes buffer, pH 7.4, con-
taining freshly added protease inhibitors (0 .1 mM PMSF, 1 /Ag/ml
each of antipain, leupeptin, aprotinin, and pepstatin A) followed
by centrifugation at 1,000 g for 10 min at 4 °C . For two-dimensional
gels, this supernatant (Sl) was centrifuged at 170,000 g for 2 h
at 4°C and the resulting supernatant was analyzed by the proce-
dure described by O'Farrell et al. (15) and modified by Ames and
Nikaico (16) . Western blotting was performed as described (6, 14)
using I'll-protein A. Patient sera were used at the dilution of
1:250 .
Cell Fractionation and Triton X-114 PhaseSeparation. A postnuclear
supernatant of rat brain (Sl) was prepared as described above. Sl
was centrifuged at 36,000 g for 30 min at 4°C. The resulting su-
pernatant (S2) was separated into particulate (P3) and cytosolic (S3)
fractions by centrifugation at 170,000 g for 2 h at 4°C . P3 and
S3 were extracted in 2% Triton X-114, and insoluble material was
removed by centrifugation at 20,000 g for 30 min at 4°C . The
soluble material was separated into detergent (D) and aqueous (A)
phases as described (17) . Volumes loaded in each lane were normal-
ized so that corresponding aliquots of supernatants and pellets (or
detergent and aqueous phases) were loaded for each pair offractions.
Immunoprecipitation. A soluble fraction of rat brain (S3) pre-
pared as described above was extracted in ice-cold 2% Triton X-100,
150 mM NaCl, 10 mM Hepes, pH 7.4, for 2 h. Insoluble material
was removed by centrifugation at 20,000g for 30 min at 4°C. The
resulting supernatant was diluted with an equal volume of 150mM
NaCl, 10 mM Hepes, pH 7.4 (buffer A), to a final protein concen-
tration of 1 mg/ml. 900-P,1 aliquots of extract were precleared as
described (5) and used for each immunoprecipitation . For immu-
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noprecipitation, the following additions were made in sequential
order: (a) 25 gl human sera (16 h) ; (b) 20 wl rabbit anti-human
IgGs (1 .5 h) ; and (c) 125 pl 50% protein A-Sepharose in buffer
A (1.5 h) . All incubations were performed at 4°C with rotation .
Immunoprecipitated material was recovered and analyzed by Western
blotting as described (14) .
Results and Discussion
Fig. 1 shows Western blots of total rat brain homogenate
demonstrating that the 128-kD antigen, i.e ., the protein rec-
ognized by the sera of BC-SMS patient (lanes 1-3), has the
same electrophoretic mobility in SDS-PAGE as the protein
recognized by rabbit serum (lane 4) and affinity-purified an-
tibodies (lane 5) raised against a chicken amphiphysin fusion
protein. Chicken amphiphysin was calculated to have a mo-
lecular mass of 75,204 daltons, but in SDS-PAGE runs, it
had an apparent molecular mass of 115-125 kD (10) . This
molecular mass is very similar to the one of 128 kD esti-
mated here for the rat protein. Fig. 2 shows that the 128-kD
antigen and amphiphysin have an identical isoelectric point
of4.7 in two-dimensional gels. This isoelectric point is similar
to the predicted isoelectric point of 4.4, calculated on the basis
of the amino acid composition ofchicken amphiphysin (10) .
The distribution of the 128-kD antigen and ofamphiphysin
were compared in the course of subcellular fractionation of
brain homogenates. As shown in Fig. 3, a and b, both the
autoantigen and amphiphysin were present in roughly equal
amounts in a cytosolic fraction (S3) and in a particulate frac-
tion (P3) obtained from rat brain. Synaptophysin, an intrinsic
membrane protein of synaptic vesicles, was present exclusively
in the particulate fraction (P3) (Fig. 3 c), demonstrating that
the centrifugation conditions used were sufficient to sediment
all membranes. Membrane-bound amphiphysin was previously
shown to be recovered in the aqueous phase after Triton X-114
extraction and phase separation (10) . As shown in Fig. 3,
a and b, both the 128-kD antigen and amphiphysin were com-
pletely solubilized by Triton X-114 and were recovered ex-
clusively in the aqueous phase irrespectively of whether the
extraction was performed on P3 or S3 (Fig. 3, a and b) . The
effectiveness of phase separation conditions was confirmed
by the presence ofthe bulk ofsynaptophysin (a protein with
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Figure 1 . The 128-kD antigenand
amphiphysin have identical electro-
phoretic mobilities in SDS gels .
Western blots of total rat brain ho-
mogenate probed with sera of three
BC-SMS patients and rabbit antiam-
phiphysin antibodies (lane 4, crude
serum [Amph-S] ; lane 5, affinity-
purified antibodies [AmphAP]). The
128-kD antigen is indicated by an
arrow. The single band of am-
phiphysin and ofthe 128-kD antigen
visible in this gel can be resolved in
a doublet oftwo closely spaced bands
under different electrophoresis condi-
tions (9, 10) .
Figure 2 .
	
The 128-kD antigen and amphiphysin have identical elec-
trophoretic mobilities in two-dimensional gels. Western blot of two-
dimensional gels of a soluble rat brain fraction probed with BC-SMS I
serum (a) andrabbit antiamphiphysin serum (b). Numbers at the top indi-
cate isoelectric points, numbers at the left indicate molecular mass markers
(in kD) .
four transmembrane regions (18)) in the detergent phase ob-
tained from P3 (Fig. 3 c) .
The 128-kD antigen and amphiphysin were found to be
immunologically cross-reactive. To prove that antiamphiphysin
antibodies recognize the 128-kD antigen, BC-SMS patient
sera were used to immunoprecipitate the 128-kD antigen from
soluble extracts of rat brain . The presence of amphiphysin
in the immunoprecipitate was then analyzed by Western blot-
ting using antiamphiphysin serum. An immunoreactive band
with electrophoretic mobility of 128 kD was detected (Fig.
4 a, lanes 1-3) while no GAD was recovered in the same
immunoprecipitates (Fig. 4 b, lanes 1-3) confirming previous
Figure 3. The 128-kD antigen and amphiphysin partition similarly in
differential centrifugation and Triton X-114 phase separation. Particulate
(P3) and cytosolic (S3) fractions of rat brain were extracted in Triton X-114
and centrifuged to obtain a soluble (sol) and an insoluble (ins) fraction .
The Triton X-114-soluble material (lanes 3 and 8) was separated into de-
tergent (D; lanes 4 and 9) and aqueous (A ; lanes 5 and 10) phases. The
fractions were probed by immunoblotting with antiamphiphysin affinity-
purified antibodies (AmphAP), with BC-SMS 1 serum (BC-SMS 1), and
with antisynaptophysin serum (Synapt-S) . The 128-kD antigen and am-
phiphysin were recovered in both the cytosolic (S3) and in the particulate
(P3) fractions, and exclusively in the Triton X-114 aqueous phase derived
from these fractions. Synaptophysin, which is an integral membrane pro-
tein with four transmembrane spanning domains, is recovered only in P3
and primarily in the detergent phase derived from the Triton X-114-soluble
material obtained from P3.
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Figure 4. BC-SMS patient sera immu-
noprecipitate amphiphysin from rat brain
extracts . Immunoprecipitates obtained
with the sera of three BC-SMS patients
(lanes 1-3) and with the serum of a SMS
patient positive for GAD autoantibodies
(SMS-GAD) (lane 4) were separated by
SDS-PAGE. (a) Immunoblotted with
rabbit antiamphiphysin serum (Amph-S);
and (b) immunoblotted with the rabbit
anti-GAD serum no. 6799 (CADS) (12) .
results (9) . As a control, immunoprecipitation was performed
with a SMS patient serum that contained high-titer anti-GAD
antibodies (6, 8), but no antibodies against the 128-kD auto-
antigen . This immunoprecipitate was positive for GAD (Fig.
4 b, lane 4), but not for amphiphysin (Fig . 4 a, lane 4) . Con-
versely, a protein of 128 kD was detected when an immuno-
precipitate obtained with antiamphiphysin serum was im-
munoblotted with BC-SMS patient sera (not shown) . To
Figure 5 . BC-SMS patient sera recognize recombinant amphiphysin .
Western blots of three identical gel triplets reacted with sera BC-SMS 2,
3, and 4, as indicated. Lanes 1, bacterial lysate expressing a 165-kD fusion
protein of 0-galactosidase with a yet unidentified synaptic protein (clone
10.12 .1 ; B. Lichte, and M.W. Kilimann, unpublished observation) . Lanes
2, bacterial lysate expressing a 0-galactosidase-chicken amphiphysin fu-
sion protein (clone amphy-11.3 ; fusion protein size -230 kD) (10) . Lanes
3, chicken brain total homogenate. Identical results were obtained with
serum BC-SMS Knot shown) . Long and short arrows indicate the mobil-
ities of the chicken amphiphysin fusion protein and of the control fusion
protein, respectively. Bands below the major immunopositive bands of
lanes 2 most likely represent proteolytic fragments ofthe fusion protein.
An arrowhead points to chicken brain amphiphysin .
Figure 6 .
	
The 128-kD antigen
and amphiphysin have the same
tissue distribution . Western blot
of postnuclear supernatants of rat
tissues (brain, pituitary, testis,
liver) and endocrine cell lines
(PC12 cells [rat chromafrn cell
line] ; =3 cells [mouse in-
sulinoma] ; ciTC9 [mouse gluca-
gonoma]) probed with either
BC-SMS patient serum (BC-
SMS 1) or antiamphiphysin serum
(Amph-S) .
conclusively demonstrate that BC-SMS sera recognize am-
phiphysin, they were tested against bacterial lysates containing
recombinant amphiphysin as shown in Fig . 5 . BC-SMS sera
labeled a /3-galactosidase-chicken amphiphysin fusion protein
(Fig . 5, lanes 2) and chicken brain amphiphysin (Fig . 5, lanes
3), but not a control fusion protein (Fig. 5, lanes 1) .
Amphiphysin was previously shown to have a restricted
tissue distribution (10) . Amphiphysin mRNA was detected
at high levels in brain and at lower levels in adrenal gland .
By immunoblotting amphiphysin was detected in the anterior
and posterior pituitary as well (10) . The expression of am-
phiphysin was compared with that of the 128-kD antigen
in a variety of tissues and cell lines using Western blotting .
Fig. 6 shows that the serum of a BC-SMS patient and the
rabbit serum directed against amphiphysin label a similar pro-
tein in brain, pituitary, and cell lines derived from adrenal
chromaffin cells (PC12 cells) and from pancreatic a and 0
cells (oiTC9, OC3) (19, 20) but not in liver. Presence of am-
phiphysin in all cells of pancreatic islets was confirmed by
immunocytochemistry (not shown) . Endocrine cells of the
anterior pituitary, adrenal medulla, and pancreatic islets have
many biochemical and functional similarities to neurons and
contain organelles closely related to neuronal synaptic vesicles
(21, 22) . In addition, both amphiphysin and the 128-kD an-
tigen were detected in the testis (Fig . 6) . By immunocyto-
chemistry with BC-SMS sera, amphiphysin immunoreactivity
in the testis was found to be confined to germ cells. All germ
cells expressed amphiphysin irrespective of their stage of
differentiation (from spermatogonia to mature spermatozoa)
(not shown) . Previously, amphiphysin mRNA could not be
detected in chicken testis (10), but this was probably so be-
cause the RNA had been purified from immature testis of
7-d-old animals. It should be noted that GAD as well is ex-
pressed in male germ cells (23) .
These data convincingly demonstrate that the 128-kD an-
tigen is amphiphysin . Amphiphysin contains in its sequence
a hydrophobic 21-amino acid region that would be compe-
tent to form a transmembrane helix (10) . However, the
recovery of amphiphysin both in soluble and membrane frac-
tions (10) as well as the presence of a pool of the protein
detectable by immunocytochemistry throughout the neuronal
cytoplasm (9) indicate that amphiphysin is not an intrinsic
membrane protein . Like amphiphysin, GAD, the other major
autoantigen of SMS, is concentrated in nerve terminals where
it interacts with synaptic vesicles but is not an intrinsic mem-
brane protein (14, 24-26) . While GAD is expressed only by
GABA-secreting neurons, amphiphysin is not restricted to
these neurons (9, 10) .
The similar subcellular localization of GAD and am-
phiphysin is intriguing if one considers that they are the only
two known targets of CNS autoimmunity with this distri-
bution . This observation raises the possibility that pathogenetic
mechanisms in SMS may be linked to CNS autoimmunity
directed against presynaptic components that interact with
synaptic vesicles. Autoantibodies directed against GAD and
amphiphysin are not likely to be directly pathogenetic be-
cause antibodies are not thought to have access to the cyto-
plasmic compartment . They may represent the dominant au-
toantibody species in the context of an autoimmune response
directed against multiple antigens (27), including proteins
exposed at the cell surface that may be the pathogenetic targets
of the autoimmune response. Alternatively, these autoanti-
bodies may reflect an autoimmune reaction in which T cells
are the primary players. GAD and amphiphysin autoantibodies
segregate with two SMS patient subpopulations, each charac-
terized by different associated diseases . GAD autoanti-
body-positive SMS is often associated with organ-specific au-
toimmune diseases and primarily insulin-dependent diabetes
mellitus (3-7) . Amphiphysin autoantibody-positive SMS
occurs only in association with cancer (9) and has the charac-
teristics of an autoimmune paraneoplastic syndrome (28, 29) .
Therefore, the two patterns of autoimmunity are likely to
be related to these different associated conditions . Further
studies of antiamphiphysin autoimmunity and of the func-
tion of amphiphysin or amphiphysin-related molecules not
only may shed some light on pathogenetic mechanisms in
SMS, but may also help in the elucidation of the biology of
at least some types of cancer. Although amphiphysin was not
detected in breast cancer tissue (9), it will be of interest to
determine whether amphiphysin-related proteins are expressed
in breast cancer.
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